Last updated: September 22, 2026
Efalizumab, marketed as Raptiva by Genentech and Merck Serono, was a humanized monoclonal antibody approved for moderate-to-severe plaque psoriasis. Its commercial trajectory ended after reports of progressive multifocal leukoencephalopathy, or PML, a rare and frequently fatal opportunistic brain infection. Genentech withdrew Raptiva from the U.S. market in April 2009, and European regulators suspended and later withdrew its authorization. The product has no current commercial market, no active branded revenue base, and no meaningful generic or biosimilar launch opportunity.
What was efalizumab and how did it work?
Efalizumab was a recombinant humanized IgG1 monoclonal antibody targeting CD11a, the alpha subunit of the lymphocyte function-associated antigen-1, or LFA-1. By binding CD11a, efalizumab reduced T-cell adhesion, trafficking, and activation involved in psoriasis inflammation.
| Attribute |
Efalizumab |
| Brand |
Raptiva |
| Active ingredient |
Efalizumab |
| Drug class |
Humanized monoclonal antibody |
| Target |
CD11a/LFA-1 |
| Initial indication |
Moderate-to-severe plaque psoriasis |
| Administration |
Subcutaneous injection |
| U.S. sponsor |
Genentech |
| European commercial partner |
Merck Serono |
| U.S. approval |
October 2003 |
| European authorization |
2004 |
| U.S. withdrawal |
April 2009 |
| Primary withdrawal issue |
PML and serious opportunistic infections |
The product was administered weekly after an initial weight-based dose. Its mechanism differed from tumor necrosis factor inhibitors and later interleukin-17 and interleukin-23 therapies, but its safety profile and limited long-term durability reduced its commercial competitiveness.
What was the market position of Raptiva?
Raptiva entered a psoriasis market that already included systemic therapies, phototherapy, methotrexate, cyclosporine, and biologics such as etanercept. Its principal commercial advantage was a targeted immune mechanism delivered by subcutaneous injection. Its disadvantages included weekly dosing, a boxed warning for serious infections and malignancies, acute dosing-related reactions, and the requirement for continued treatment to maintain disease control.
The product competed directly with established psoriasis biologics and indirectly with newer agents that later achieved stronger efficacy profiles. Raptiva never became a category-leading biologic.
How did efalizumab compare with competing psoriasis biologics?
| Product |
Target or mechanism |
Commercial position during Raptiva era |
Relative effect on Raptiva |
| Efalizumab |
CD11a/LFA-1 |
Niche psoriasis biologic |
Baseline product |
| Etanercept |
TNF inhibitor |
Established psoriasis and rheumatology franchise |
Stronger physician familiarity |
| Infliximab |
TNF inhibitor |
High-efficacy infusion biologic |
More effective for severe disease |
| Adalimumab |
TNF inhibitor |
Broad immunology franchise |
Expanded competitive pressure |
| Ustekinumab |
IL-12/23 inhibitor |
Approved in 2009 for plaque psoriasis |
Entered near Raptiva’s withdrawal |
| Secukinumab |
IL-17A inhibitor |
Later high-efficacy psoriasis therapy |
Eliminated residual commercial rationale |
| Guselkumab |
IL-23 inhibitor |
Later high-efficacy therapy |
Made re-entry commercially unattractive |
The psoriasis market shifted toward biologics with higher skin-clearance rates, longer dosing intervals, and broader label utility. Raptiva’s withdrawal removed the product before it could participate in that later market expansion.
What were efalizumab’s sales and financial trajectory?
Efalizumab generated modest revenue relative to major biologics. Genentech reported Raptiva product sales of approximately $123 million in 2008, down from roughly $134 million in 2007. Earlier sales were lower and had not established a growth trajectory comparable with Genentech’s oncology and immunology blockbusters (Genentech, 2009).
| Year |
Approximate Raptiva sales |
Market interpretation |
| 2006 |
Approximately $110 million |
Established niche product |
| 2007 |
Approximately $134 million |
Peak commercial period |
| 2008 |
Approximately $123 million |
Decline before withdrawal |
| 2009 |
No sustained full-year opportunity |
Product withdrawn in April |
| 2010 onward |
Zero meaningful branded sales |
Commercial market ended |
The financial exposure was limited at the corporate level but material for a discontinued product. Raptiva’s revenue was small compared with Genentech’s leading products, including Avastin, Herceptin, and Rituxan. The withdrawal also created costs associated with patient notification, inventory removal, pharmacovigilance, regulatory action, and litigation risk.
The product’s revenue decline reflected more than safety concerns. Physicians had access to competing biologics with stronger efficacy or broader commercial support. Raptiva also required continuing weekly injections and had no meaningful expansion into adjacent immune-mediated diseases.
Why was efalizumab withdrawn from the market?
Efalizumab was withdrawn after three confirmed cases of PML, including two deaths, were reported in patients receiving long-term therapy. The FDA and Genentech concluded that the risk could not be adequately managed through labeling and monitoring alone (U.S. Food and Drug Administration, 2009a).
The withdrawal process included:
- Genentech’s April 2009 voluntary withdrawal from the U.S. market.
- A recommendation that patients discontinue treatment under physician supervision.
- European suspension and subsequent withdrawal of the marketing authorization.
- Continued safety surveillance for patients previously exposed to the product.
PML is associated with reactivation of John Cunningham virus in immunosuppressed patients. The event changed the product’s risk-benefit assessment from a commercial and regulatory perspective. Raptiva’s psoriasis indication did not justify continued exposure when alternative biologics were available.
What was the FDA regulatory status of efalizumab?
The FDA approved Raptiva in 2003 for adults with chronic moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy. The product carried progressively stronger safety warnings as postmarketing reports accumulated.
The FDA issued a public health communication in February 2009 after identifying PML cases in patients treated with Raptiva. Genentech announced the U.S. withdrawal in April 2009. The FDA later advised healthcare professionals about treatment discontinuation, patient monitoring, and the need to assess prior Raptiva exposure (U.S. Food and Drug Administration, 2009a, 2009b).
Raptiva is not an FDA-approved active product today. There is no current FDA-approved efalizumab reference product marketed for psoriasis.
What is the Orange Book status of efalizumab?
Raptiva is not a commercially active product in the current U.S. market, and its withdrawal eliminates a practical abbreviated new drug application, or ANDA, pathway for a conventional generic product. Efalizumab was a biologic, not a small-molecule drug, so a follow-on product would require a biologics pathway rather than a standard generic substitution model.
The relevant regulatory distinction is:
- A generic efalizumab product would not be developed through ordinary small-molecule ANDA substitution.
- A biosimilar or interchangeable product would require an appropriate biologics application and a commercially viable reference product.
- Withdrawal for safety reasons makes a follow-on program commercially and regulatorily unattractive.
- No meaningful current U.S. biosimilar development program is publicly associated with efalizumab.
What patents protected efalizumab?
Efalizumab’s original patent estate was based primarily on antibody composition, anti-CD11a binding, therapeutic use, and manufacturing technology. The core U.S. patent term for the original discovery portfolio would have been tied to applications filed in the 1980s and 1990s. Those terms have expired or are no longer commercially relevant.
The practical position is:
| Patent category |
Commercial status |
| Anti-CD11a antibody composition |
Historical protection; no current commercial barrier |
| Humanized antibody sequence |
Historical protection; term expired or commercially exhausted |
| Psoriasis treatment methods |
Historical protection; no effective market exclusivity |
| Subcutaneous dosing regimen |
No meaningful current exclusivity |
| Manufacturing and cell-line technology |
Potentially narrow historical rights; not a practical market barrier |
| Formulation patents |
No known active commercial protection supporting a marketable Raptiva franchise |
Publicly accessible records do not establish a current, enforceable patent estate capable of supporting re-commercialization. Patent expiration is no longer the central issue. The safety withdrawal, lack of regulatory demand, and availability of alternative therapies control the product’s commercial status.
When did efalizumab lose market exclusivity?
Efalizumab lost practical exclusivity when Genentech withdrew Raptiva in 2009. The product’s economic exclusivity ended before any conventional generic or biosimilar competitor could establish a market.
The distinction between legal patent expiry and commercial exclusivity is important:
- Legal patent rights may have extended beyond the withdrawal date for specific claims.
- Those rights did not preserve a viable revenue stream.
- Regulatory withdrawal prevented ordinary commercial exploitation of the brand.
- No competitor needed to challenge Raptiva patents to enter the active psoriasis market because other biologics already occupied the treatment space.
Were there Paragraph IV challenges to efalizumab?
No material Paragraph IV litigation or commercially consequential ANDA challenge is associated with efalizumab. That outcome is consistent with the product’s biologic status and its withdrawal before a generic-style market developed.
A Paragraph IV strategy would have offered limited value because:
- Efalizumab was a biologic rather than a conventional small molecule.
- A follow-on applicant would face substantial clinical, manufacturing, and regulatory costs.
- PML risk would complicate benefit-risk justification.
- The commercial market had shifted toward competing biologics.
Was there biosimilar risk for efalizumab?
Biosimilar risk is effectively zero as a commercial threat to the original product because the branded market no longer exists. A theoretical biosimilar program would face several barriers:
- No active marketed reference product with meaningful physician demand.
- Limited clinical rationale for reintroducing a product linked to PML.
- Strong competition from TNF, IL-17, and IL-23 inhibitors.
- High analytical and clinical development costs.
- Potential product-liability exposure.
- Weak payer and prescriber incentives.
Efalizumab is therefore a discontinued biologic, not an approaching biosimilar-loss-of-exclusivity asset.
What patent litigation and settlement agreements affected efalizumab?
No major patent litigation or settlement agreement materially shaped efalizumab’s market outcome. The decisive legal and regulatory event was the product withdrawal, not a patent ruling or generic settlement.
The absence of major Paragraph IV settlements also means there was no negotiated generic launch date, authorized generic strategy, or patent cliff comparable with major small-molecule medicines.
What manufacturing and intellectual-property barriers remain?
Manufacturing efalizumab would require a validated mammalian-cell production process, control of glycosylation and aggregation, viral clearance, potency testing, and clinical comparability. Those technical requirements would be substantial for a new developer.
They are not, however, the main barrier. The principal barriers are commercial and regulatory:
- The product’s PML history.
- Lack of a compelling unmet need.
- More effective psoriasis therapies.
- Physician reluctance to adopt a withdrawn immune-modulating antibody.
- Limited reimbursement rationale.
- No established manufacturing or commercial infrastructure.
Any residual know-how from the original production process would not create a durable competitive moat because modern biologics manufacturers can develop alternative processes.
What is the competitive outlook for efalizumab?
Efalizumab has no meaningful competitive outlook as an active commercial drug. Its former market has been absorbed by newer biologics with better efficacy, dosing convenience, and safety-management profiles.
The strongest competitive substitutes include adalimumab, ustekinumab, secukinumab, ixekizumab, guselkumab, risankizumab, and deucravacitinib. These products benefit from established treatment guidelines, payer coverage, and clinical experience.
A re-entry scenario would require a new indication, a materially different risk-benefit profile, and a new development program. The probability of such a program is commercially negligible.
Key Takeaways
- Efalizumab was marketed as Raptiva for moderate-to-severe plaque psoriasis.
- Genentech withdrew the product in April 2009 after confirmed PML cases and deaths.
- Peak annual sales were approximately $134 million in 2007, followed by a decline to about $123 million in 2008.
- The product has no current branded revenue base.
- No material Paragraph IV challenge, generic launch, biosimilar program, or settlement agreement affected its market.
- Historical composition, method-of-use, formulation, and manufacturing patent rights no longer create a practical commercial barrier.
- The principal barriers to re-entry are safety history, weak market demand, regulatory risk, and competition from newer psoriasis biologics.
- Efalizumab is a discontinued biologic with no credible near-term licensing, launch, or investment thesis.
FAQs
Could efalizumab be repurposed for another autoimmune disease?
A theoretical repurposing program would require new clinical trials and a new benefit-risk assessment. The PML history would make development difficult, particularly where safer targeted therapies are available.
Is Raptiva still available outside the United States?
Raptiva was withdrawn or had its authorization suspended in major regulated markets, including Europe. It should not be treated as an actively marketed international product.
Did efalizumab have pediatric exclusivity?
The product was not commercially sustained long enough for pediatric exclusivity to create a meaningful market extension. No current pediatric exclusivity period supports market access.
What was the main reason Raptiva failed commercially?
The central cause was the emergence of PML and the resulting withdrawal. Competitive disadvantages in efficacy, dosing, and treatment choice amplified the commercial decline.
Could a company acquire efalizumab rights today?
A rights transaction would have little economic value unless tied to a new development strategy. Historical intellectual property and brand rights do not provide a viable active-market franchise.
References
Genentech, Inc. (2009). Annual report 2008. South San Francisco, CA: Author.
U.S. Food and Drug Administration. (2009a). FDA public health advisory: Raptiva (efalizumab) and progressive multifocal leukoencephalopathy. Silver Spring, MD: Author.
U.S. Food and Drug Administration. (2009b). Information for healthcare professionals: Efalizumab marketed as Raptiva. Silver Spring, MD: Author.
European Medicines Agency. (2009). European Medicines Agency recommends suspension of the marketing authorisation for Raptiva. London, UK: Author.
